<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45145">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518594</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801-PROSPECT</org_study_id>
    <nct_id>NCT02518594</nct_id>
  </id_info>
  <brief_title>A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix</brief_title>
  <acronym>PROSPECT</acronym>
  <official_title>A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol outlines a randomized trial of 600 women evaluating the use of micronized
      vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in
      women carrying twins and with a cervical length of less than 30 millimeters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple gestation increases the risk of preterm delivery. Babies born preterm have
      increased rates of neonatal mortality and long-term neurodevelopmental morbidities. Short
      cervical length is known to be an important risk factor for spontaneous preterm birth and to
      occur more frequently in women with a twin gestation. Although there is no evidence that
      progesterone reduces the risk of preterm birth in multifetal gestation, there is evidence
      that progesterone reduces the risk of prematurity in singleton gestations complicated with a
      short cervix. The Arabin pessary has also been shown to reduce the risk of preterm birth
      among singletons with a short cervix, and in a secondary subgroup analysis of a recent study
      of the use of pessary in multiple gestations, women with a cervical length &lt; 25th percentile
      had a significantly reduced risk of the primary composite neonatal adverse outcome.
      Secondary analysis of studies of vaginal progesterone in multiple gestation with a short
      cervix also suggest a possible beneficial effect on preterm delivery.

      This protocol outlines a randomized trial of 600 women evaluating the use of micronized
      vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in
      women carrying twins and with a cervical length of less than 30 millimeters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery prior to 35 weeks or fetal loss</measure>
    <time_frame>prior to 35 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Randomization to delivery interval</measure>
    <time_frame>16 to 42 weeks</time_frame>
    <description>Randomization may begin at 16 weeks, and most patient will be delivered by 41 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>16 to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity and mortality</measure>
    <time_frame>16 to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower genital tract or urinary tract infection</measure>
    <time_frame>16 to 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician interventions</measure>
    <time_frame>16 to 42 weeks</time_frame>
    <description>Composite measure. Includes bedrest, cerclage, labor inhibition therapy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Short Cervical Length</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg micronized vaginal progesterone softgel capsule, daily from randomization to &lt; 35 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo softgel capsule, daily from randomization to &lt; 35 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arabin Pessary</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placement management from randomization to &lt; 35 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal progesterone</intervention_name>
    <description>200mg micronized vaginal progesterone softgel capsule, daily from randomization to &lt; 35 wks</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Endometrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo softgel capsule, daily from randomization to &lt; 35 wks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arabin Pessary</intervention_name>
    <description>Placement management from randomization to &lt; 35 wks</description>
    <arm_group_label>Arabin Pessary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Twin gestation with cardiac activity in both fetuses. Higher order multifetal
             gestations reduced to twins, either spontaneously or therapeutically, are not
             eligible unless the reduction occurred before 12 weeks project gestational age (see
             below).

          2. Gestational age at randomization between 16 weeks 0 days and 23 weeks 6 days based on
             clinical information and evaluation of the earliest ultrasound as described in
             Gestational Age Determination in Section 3.4.2 below;

          3. Cervical length on transvaginal examination of less than 30 mm within 14 days prior
             to randomization by a study certified sonographer.

        Exclusion Criteria:

          1. Cervical dilation (internal os) 2 cm or greater on digital examination or evidence of
             prolapsed membranes beyond the external cervical os either at the time of the
             qualifying cervical ultrasound examination or at a cervical exam immediately before
             randomization. There is no lower threshold of cervical length measurement threshold
             on ultrasound that is an exclusion criterion.

          2. Monoamniotic gestation, due to increased risk of adverse pregnancy outcome

          3. Twin-twin transfusion syndrome, due to increased risk of adverse pregnancy outcome

          4. Evidence of severe IUGR (intrauterine growth restriction) (&lt;5th percentile for
             gestational age) in either fetus

          5. Fetal anomaly in either twin or imminent fetal demise. This includes lethal
             anomalies, or anomalies that may lead to early delivery or increased risk of neonatal
             death e.g., gastroschisis, spina bifida, serious karyotypic abnormalities). An
             ultrasound examination from 14 weeks 0 days to 23 weeks 6 days by project EDC
             (estimated date of conception) must be performed prior to randomization to evaluate
             the fetuses for anomalies.

          6. Placenta previa, because of risk of bleeding and high potential for indicated preterm
             birth

          7. Active vaginal bleeding greater than spotting at the time of randomization, because
             of potential exacerbation due to pessary placement

          8. Symptomatic, untreated vaginal or cervical infection, also because of potential
             exacerbation due to pessary placement. Patients may be treated and if subsequently
             asymptomatic, randomized.

          9. Rupture of membranes due to likelihood of pregnancy loss and preterm delivery as well
             as the risk of ascending infection which could be increased with pessary placement

         10. More than six contractions per hour reported or documented prior to randomization. It
             is not necessary to place the patient on a tocodynamometer

         11. Known major Mullerian anomaly of the uterus (specifically bicornuate, unicornuate, or
             uterine septum not resected) due to increased risk of preterm delivery which is
             unlikely to be affected by progesterone

         12. Any fetal/maternal condition which would require invasive in-utero assessment or
             treatment, for example significant red cell antigen sensitization or neonatal
             alloimmune thrombocytopenia

         13. Major maternal medical illness associated with increased risk for adverse pregnancy
             outcome or indicated preterm birth (treated hypertension requiring more than one
             agent, pre-gestational treatment for diabetes prior to pregnancy, chronic renal
             insufficiency failure defined by creatinine &gt;1.4 mg/dL, carcinoma of the breast,
             conditions treated with chronic oral glucocorticoid therapy. Specifically, patients
             with seizure disorders, HIV, and other medical conditions not specifically associated
             with an increased risk of indicated preterm birth are not excluded. Prior cervical
             cone/LOOP/LEEP is not an exclusion criterion.

         14. Planned cerclage or cerclage already in place since it would preclude placement of a
             pessary

         15. Planned indicated delivery prior to 35 weeks

         16. Planned or actual progesterone treatment of any type or form after 14 weeks 6 days
             during the current pregnancy

         17. Allergy to progesterone or excipients in the study drug or placebo

         18. Participation in another interventional study that influences gestational age at
             delivery or neonatal morbidity or mortality

         19. Participation in this trial in a previous pregnancy. Patients who were screened in a
             previous pregnancy, but not randomized, do not have to be excluded.

         20. Prenatal care or delivery planned elsewhere unless the study visits can be made as
             scheduled and complete outcome information can be obtained
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Biggio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maternal Fetal Medicine Units (MFMU) Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uma Reddy, MD, MPH</last_name>
    <phone>301-496-1074</phone>
    <email>reddyu@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Thom, PhD</last_name>
    <phone>301-881-9260</phone>
    <email>e_thom@bsc.gwu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Harris, RN BSN</last_name>
      <phone>205-934-1322</phone>
      <email>stacylharris@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan TN Tita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Willson, RN BSN</last_name>
      <phone>650-724-6372</phone>
      <email>cwillson@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Yasser El-Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Hale, RN BSN</last_name>
      <phone>303-724-6685</phone>
      <email>kathy.a.hale@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Kent Heyborne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University-Prentice Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Mallett</last_name>
      <phone>312-503-3200</phone>
      <email>g-mallett@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>William Grobman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Bousleiman</last_name>
      <phone>212-305-4348</phone>
      <email>sb1080@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Wapner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Clark, RN</last_name>
      <phone>919-350-6117</phone>
      <email>kelly_clark@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Thorp, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy S Bishop, RNC MSN</last_name>
      <phone>919-668-7475</phone>
      <email>sincl008@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Geeta K Swamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Dalton, RNC</last_name>
      <phone>216-778-7533</phone>
      <email>wdalton@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Edward Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francee Johnson, RN BSN</last_name>
      <phone>614-293-5632</phone>
      <email>johnson.126@osu.edu</email>
    </contact>
    <investigator>
      <last_name>Jay D Iams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Allard, RNC</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>8522</phone_ext>
      <email>dallard@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Dwight Rouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Moseley, RN</last_name>
      <phone>214-648-2591</phone>
      <email>lisa.moseley@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Casey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Salazar, RN MSN WHNP</last_name>
      <phone>409-772-0312</phone>
      <email>assalaza@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>George Saade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felecia Ortiz, RN</last_name>
      <phone>713-500-6467</phone>
      <email>Felecia.Ortiz@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Suneet Chauhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hill, RN BSN</last_name>
      <phone>801-585-5586</phone>
      <email>Kim.Hill@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael W Varner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 18, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>women</keyword>
  <keyword>cervical length of less than 30 millimeters</keyword>
  <keyword>carrying twins</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
